Karo Pharma AB (KARO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases including autoimmune diseases such as multiple sclerosis; and multiple types of cancer, viral and bacterial infections. The companys projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 11
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 13
Partnerships 15
Karo Bio Enters Into Research Agreement With 4D Science 15
Licensing Agreements 16
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 16
Equity Offering 17
Karo Pharma to Raise USD151.5 Million in Rights Offering of Shares 17
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 18
Karo Bio Raises USD29 Million in Rights Offering of Shares 19
Karo Bio Raises USD12 Million in Rights Offering of Shares 20
Karo Bio Raises USD1 Million in Private Placement of Shares 21
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 22
Asset Transactions 23
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 23
Acquisition 24
Karo Pharma Acquires Weifa 24
Karo Pharma Acquires 100% Stake in Medireduce 26
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 27
Karo Bio Acquires Tanomed for USD2.3 Million 28
Aqualis Completes Acquisition of Weifa for USD183.6 Million 29
Karo Pharma AB - Key Competitors 30
Karo Pharma AB - Key Employees 31
Karo Pharma AB - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Apr 26, 2018: Karo Pharma Doubles Sales and Earnings in the First Quarter 33
Feb 22, 2018: Karo Pharma: Year-end Report 2017 34
Nov 02, 2017: Karo Pharma: Interim Report January September 2017 35
Aug 24, 2017: Karo Pharma: Interim Report JanuaryJune 2017 37
May 10, 2017: Karo Pharma: interim report January - March-2017 38
Feb 28, 2017: Karo Pharma: Full Year Report 2016 39
Corporate Communications 40
Mar 23, 2018: Karo Pharma Supports Operation Smile 40
Product News 41
05/21/2018: UTILITY Therapeutics Receives Qualified Infectious Disease Product Designation from the U.S. FDA for Mecillinam 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List Of Tables

List of Tables
Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 11
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 13
Karo Bio Enters Into Research Agreement With 4D Science 15
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 16
Karo Pharma to Raise USD151.5 Million in Rights Offering of Shares 17
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 18
Karo Bio Raises USD29 Million in Rights Offering of Shares 19
Karo Bio Raises USD12 Million in Rights Offering of Shares 20
Karo Bio Raises USD1 Million in Private Placement of Shares 21
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 22
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 23
Karo Pharma Acquires Weifa 24
Karo Pharma Acquires 100% Stake in Medireduce 26
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 27
Karo Bio Acquires Tanomed for USD2.3 Million 28
Aqualis Completes Acquisition of Weifa for USD183.6 Million 29
Karo Pharma AB, Key Competitors 30
Karo Pharma AB, Key Employees 31
Karo Pharma AB, Subsidiaries 32

List Of Figures

List of Figures
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 11

Karo Pharma AB (KARO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune

USD 250 View Report

Karo Pharma AB (KARO) - Financial and Strategic SWOT Analysis Review

Karo Pharma AB (KARO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Asarina Pharma AB (ASAP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Asarina Pharma AB (Asarina Pharma), formerly Umecrine Mood AB, a subsidiary of Umecrine AB, is a sepranolone product developer. The company offers discovery, development and commercialization of novel treatments for

USD 250 View Report

Xspray Pharma AB (XSPRAY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Xspray Pharma AB (Xspray Pharma), formerly Xspray Microparticles AB, is a drug development company that develops and commercializes protein kinase inhibitors (PKI) for targeted cancer treatments. The companys drug candidates

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available